Hematology Reports · Published 2026-06-10 · DOI 10.3390/hematolrep18030040
Caterina Alati, Martina Pitea, Gaetana Porto, Giorgia Policastro, Erica Bilardi, Giovanna Utano, Laura Giordano, Annalisa Sgarlata, Ilaria Maria Delfino, Aurora Idato, Giulia Santoro, Filippo Antonio Canale, Virginia Naso, Massimo Martino
<b>Background</b>: Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the management of relapsed or refractory hematologic malignancies, achieving high response rates in B-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and multiple myeloma. While the efficacy of CAR-T therapy is well established, quality of life (QoL) metrics have become increasingly important for guiding treatment decisions, patient counseling, and survivorship planning. <b>Objectives</b>: Most patients undergoing CAR-T therapy recover their initial QoL within 3 months, an improvement not typically seen with other treatment options. A comprehensive understanding of QoL is essential for delivering patient-centered care in the evolving CAR-T landscape. <b>Conclusions</b>: This review synthesizes current evidence on QoL outcomes in CAR-T recipients, including acute effects, recovery trajectories, comparisons with conventional therapies, and strategies to optimize QoL.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →
Alati, C., Pitea, M., Porto, G., et al. (2026). Quality of Life in CAR-T Cell Therapy. Hematology Reports. https://doi.org/10.3390/hematolrep18030040